Synpromics named as prominent player in UK SynBio sector

In a recent blog by SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology, Synpromics is listed as one of 7 prominent players in the UK’s thriving synthetic biology sector. 

The blog takes a look at companies leading the way in UK synthetic biology, creating innovative new technologies and driving the growth of the UK bioeconomy.

Synpromics recent expansion, funding successes and move to new facilities at the Roslin Innovation Centre, were also credited in the blog. This is further recognition of the rapid development Synpromics are making as a company, and testament to the fact that others working in the sector are taking notice of Synpromics as a prominent player and one to watch.

Synpromics develops and commercialises synthetic promoters, which control the expression of particular human or non-human genes, and have a range of uses, including biotechnology manufacturing and gene therapy.

Synpromics is expanding rapidly to meet increasing global demand for its cutting-edge gene control technology, growing its team by over 100% in recent years and moving into new world-class facilities at the Roslin Innovation Centre in September 2017.

The Company has also developed PromPT™, its proprietary synthetic promoter development platform, utilising a multi-dimensional bioinformatics database, to enable product-specific promoter design and selection.